Lineage Announces Issuance Of U.S. Patent Covering Proprietary Manufacturing And Differentiation Process For Retinal Pigmented Epithelial Cells
Portfolio Pulse from Benzinga Newsdesk
Lineage Cell Therapeutics, Inc. (LCTX) has been granted a U.S. patent for its proprietary manufacturing and differentiation process for retinal pigmented epithelial cells. The patent, which is exclusively licensed to Lineage, is expected to expire on July 28, 2036. The patented process is used in the development of RG6501 (OpRegen®), a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The program is being developed in collaboration with Roche and Genentech.
October 11, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lineage Cell Therapeutics has been granted a patent that enhances the value of its lead program, OpRegen, and supports long periods of exclusivity to its pipeline of cell transplant programs.
The issuance of the patent enhances the value of Lineage's lead program, OpRegen, and provides a competitive advantage by ensuring exclusivity to its pipeline of cell transplant programs. This could potentially attract more investors and increase the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100